Last 5.38 GBp
Change Today -0.125 / -2.27%
Volume 596.8K
PLE On Other Exchanges
As of 11:30 AM 12/17/14 All times are local (Market data is delayed by at least 15 minutes).

plethora solutions holdings (PLE) Snapshot

5.50 GBp
Previous Close
5.50 GBp
Day High
5.50 GBp
Day Low
5.13 GBp
52 Week High
03/26/14 - 14.63 GBp
52 Week Low
12/15/14 - 5.13 GBp
Market Cap
Average Volume 10 Days
-0.03 GBp
Shares Outstanding
Dividend Yield

Related News

No related news articles were found.

plethora solutions holdings (PLE) Related Businessweek News

No Related Businessweek News Found

plethora solutions holdings (PLE) Details

Plethora Solutions Holdings plc, a specialty pharmaceutical company, develops and markets drugs for the treatment and management of urological disorders in the area of men’s sexual health in the United Kingdom. Its products include PSD502, a treatment for premature ejaculation. The company was founded in 2004 and is based in Chalgrove, the United Kingdom.

5 Employees
Last Reported Date: 04/23/14
Founded in 2004

plethora solutions holdings (PLE) Top Compensated Officers

Co-Founder, Chief Technical Officer, Chief Sc...
Total Annual Compensation: 137.0K GBP
Chief Financial Officer, Director and Member ...
Total Annual Compensation: 29.0K GBP
Compensation as of Fiscal Year 2013.

plethora solutions holdings (PLE) Key Developments

Plethora Solutions Holdings PLC Announces Receipt of €5 million Upfront Licensing Agreement Payment from Recordati

Plethora Solutions Holdings PLC announced that it has received the €5 million upfront payment from Recordati as per the terms of their licensing agreement for FORTACIN (PSD502) announced on 16 September 2014. The agreement grants Recordati the rights to commercialize FORTACIN in the European Union, along with Russia, the Commonwealth of Independent States (C.I.S), Turkey and certain countries of North Africa. FORTACIN is a topical spray for the treatment of premature ejaculation containing lidocaine and prilocaine in a eutectic-like mixture. FORTACIN was approved by the European Commission in November 2013. As announced by the company on 16 September 2014, under the terms of the agreement in limited circumstances, including the submission of a satisfactory feasibility report to Recordati by 31 December 2014, a portion of the upfront payment may have been refundable to Recordati and the agreement could have been terminated. The company announce that following delivery by the company to Recordati of a satisfactory feasibility report, that Recordati has confirmed that no refund is payable by the Company and that Recordati has no intention of terminating the agreement. Plethora is also pleased to report that its manufacturing partner Pharmaserve North West Limited (PSNW) expects to complete production of the first GMP batch of the six dose canisters of FORTACIN in a few days time. PSNW plans to start the second GMP batch next week and as a result the company remain on track to complete the batch stability and validation studies required for EU variation approval for the six dose canister by the end of 2014. Following completion of these studies, an application will be submitted to the European Medicines Agency (EMA) for approval of a variation of the existing marketing authorisation for the new six dose canister of FORTACIN. The company continues to expect EMA's Committee for Medicinal Products for Human Use (CHMP) approval for FORTACIN during the third quarter of 2015. It is this marketing authorization that will trigger the immediate commercial launch of the product in Europe by Recordati.

Plethora Solutions Holdings PLC Announces Approval by the European Medicines Agency for the Fortacin

Plethora Solutions Holdings PLC announced approval by the European Medicines Agency of the product name "Fortacin" for the purpose of marketing PSD502, the company's topical spray treatment for premature ejaculation, throughout the European Union. Fortacin will be marketed in the EU by Recordati, under the terms of a licensing agreement announced on 16 September 2014. The Agreement grants Recordati the rights to commercialise PSD502 in the EU, along with Russia, the Commonwealth of Independent States (C.I.S), Turkey and certain countries of North Africa.

Plethora Solutions Holdings PLC Announces License Agreement with Recordati

Plethora Solutions Holdings PLC announced that it has entered into a license agreement with Recordati. Under the terms of the License Agreement Plethora will receive a payment of EUR 5 million on the date on which the agreement becomes effective. A payment of EUR 6 million upon grant of variant approval from the European Medicines Agency for a new six dose can. A payment of up to EUR 10 million in total upon first commercial sales of PSD502 in France, Germany, Italy, Spain and Portugal (being payment of EUR 2 million for each of these 5 countries) Up to EUR 25 million in aggregate in sales-based milestones; and tiered percentage royalties on net sales, ranging from the mid-teens to the mid-twenties for 10 years from first commercial sale, and thereafter at a single digit percentage royalty rate. The License Agreement shall be effective from the date upon which agreements terminating the existing licensing and patent agreements with Shionogi, Paul Royalty Fund Holdings II and Dr. Richard Henry have become wholly unconditional, provided that this takes place by 30 September 2014. The final completion condition of the cessation agreements and Patent Transfer Agreement is receipt of funds. This completion condition is expected to be met shortly after announcement of completion of the Placing & Subscription and the Regent Pacific Subscription, which is expected to occur on 19 September 2014 and a further announcement will be made by the company in this respect.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
PLE:LN 5.38 GBp -0.125

PLE Competitors

Market data is delayed at least 15 minutes.

Company Last Change
View Industry Companies

Industry Analysis


Industry Average

Valuation PLE Industry Range
Price/Earnings NM Not Meaningful
Price/Sales -- Not Meaningful
Price/Book NM Not Meaningful
Price/Cash Flow NM Not Meaningful
TEV/Sales -- Not Meaningful

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact PLETHORA SOLUTIONS HOLDINGS, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at